Comparison of 10 Control hPSC Lines for Drug Screening in an Engineered Heart Tissue Format
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CM) are commercially available, and cardiac differentiation established routine. Systematic evaluation of several control hiPSC-CM is lacking. We investigated 10 different control hiPSC-CM lines and analyzed function and suitability for drug screening. Five commercial and 5 academic hPSC-CM lines were casted in engineered heart tissue (EHT) format. Spontaneous and stimulated EHT contractions were analyzed, and 7 inotropic indicator compounds investigated on 8 cell lines. Baseline contractile force, kinetics, and rate varied widely among the different lines (e.g., relaxation time range: 118-471 ms). In contrast, the qualitative correctness of responses to BayK-8644, nifedipine, EMD-57033, isoprenaline, and digoxin in terms of force and kinetics varied only between 80% and 93%. Large baseline differences between control cell lines support the request for isogenic controls in disease modeling. Variability appears less relevant for drug screening but needs to be considered, arguing for studies with more than one line.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Drug repositioning: identifying and developing new uses for existing drugs
Ashburn, T. T., & Thor, K. B. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1468 · Cited by 3,237
Bock, C., Kiskinis, E., Verstappen, G., Gu, H., Boulting, G., Smith, Z. D., Ziller, M., Croft, G. F., Amoroso, M. W., Oakley, D. H., et al. (2011) · Cell · doi:10.1016/j.cell.2010.12.032 · Cited by 1,009
Giacomelli, E., Meraviglia, V., Campostrini, G., Cochrane, A., Cao, X., van Helden, R. W. J., Krotenberg Garcia, A., Mircea, M., Kostidis, S., Davis, R. P., et al. (2020) · Cell Stem Cell · doi:10.1016/j.stem.2020.05.004 · Cited by 622
Common genetic variation drives molecular heterogeneity in human iPSCs
Kilpinen, H., Goncalves, A., Leha, A., Afzal, V., Alasoo, K., Ashford, S., Bala, S., Bensaddek, D., Casale, F. P., Culley, O. J., et al. (2017) · Nature · doi:10.1038/nature22403 · Cited by 586 · cited 2×
“A systematic comparison of 711 hiPSC lines from 301 donors showed that the variability of molecular signatures had a donor-dependent component, but that batches and unknown factors contributed to more than half of these (Kilpinen et al., 2017).”
BackgroundMills, R. J., Titmarsh, D. M., Koenig, X., Parker, B. L., Ryall, J. G., Quaife-Ryan, G. A., Voges, H. K., Hodson, M. P., Ferguson, C., Drowley, L., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1707316114 · Cited by 478 · cited 1×
“However, this issue should be taken into consideration when working with multicellular EHT preparations or different matrix protein such as collagen in the future (Giacomelli et al., 2020; Li et al., 2017; Mills et al., 2017; Nagaraju et al., 2019).”
BackgroundSala, L., van Meer, B. J., Tertoolen, L. G. J., Bakkers, J., Bellin, M., Davis, R. P., Denning, C., Dieben, M. A. E., Eschenhagen, T., Giacomelli, E., et al. (2018) · Circulation Research · doi:10.1161/circresaha.117.312067 · Cited by 416
Self-citationEvolution of strategies to improve preclinical cardiac safety testing
Gintant, G., Sager, P. T., & Stockbridge, N. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.34 · Cited by 407 · cited 1×
“Moreover, single ion channel assays do not allow the analysis of inotropic effects or structural cardiotoxicity, another concern in preclinical drug development (Gintant et al., 2016).”
BackgroundDenning, C., Borgdorff, V., Crutchley, J., Firth, K. S. A., George, V., Kalra, S., Kondrashov, A., Hoang, M. D., Mosqueira, D., Patel, A., et al. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2015.10.014 · Cited by 293 · cited 1×
“Cardiomyocytes (CMs) from human-induced pluripotent stem cells (hiPSC) offer great potential as a predictive human testbed for drug screening (Denning et al., 2016) and are routinely used in industrial and academic laboratories.”
BackgroundSelf-citationDifferentiation of cardiomyocytes and generation of human engineered heart tissue
Breckwoldt, K., Letuffe-Brenière, D., Mannhardt, I., Schulze, T., Ulmer, B., Werner, T., Benzin, A., Klampe, B., Reinsch, M. C., Laufer, S., et al. (2017) · Nature Protocols · doi:10.1038/nprot.2017.033 · Cited by 272 · cited 3×
“Living CM were dissociated with collagenase according to a previous protocol (Breckwoldt et al., 2017).”
MethodInfluentialSelf-citationHerron, T. J., Rocha, A. M. D., Campbell, K. F., Ponce-Balbuena, D., Willis, B. C., Guerrero-Serna, G., Liu, Q., Klos, M., Musa, H., Zarzoso, M., et al. (2016) · Circulation: Arrhythmia and Electrophysiology · doi:10.1161/circep.113.003638 · Cited by 257 · cited 1×
“5 Hz (Herron et al., 2016)matching the 435 ± 47ms wemeasured for the CDI-EHT.”
Method
Cited by
Challenges and opportunities for the next generation of cardiovascular tissue engineering
Cho, S., Discher, D. E., Leong, K. W., Vunjak-Novakovic, G., & Wu, J. C. (2022) · Nature Methods · doi:10.1038/s41592-022-01591-3 · Cited by 176
Zhuang, R. Z., Lock, R., Liu, B., & Vunjak-Novakovic, G. (2022) · Nature Biomedical Engineering · doi:10.1038/s41551-022-00885-3 · Cited by 84
Direct 3D‐Bioprinting of hiPSC‐Derived Cardiomyocytes to Generate Functional Cardiac Tissues
Esser, T. U., Anspach, A., Muenzebrock, K. A., Kah, D., Schrüfer, S., Schenk, J., Heinze, K. G., Schubert, D. W., Fabry, B., & Engel, F. B. (2023) · Advanced Materials · doi:10.1002/adma.202305911 · Cited by 75
A framework for developing sex-specific engineered heart models
Lock, R., Al Asafen, H., Fleischer, S., Tamargo, M., Zhao, Y., Radisic, M., & Vunjak-Novakovic, G. (2021) · Nature Reviews Materials · doi:10.1038/s41578-021-00381-1 · Cited by 50
Schaniel, C., Dhanan, P., Hu, B., Xiong, Y., Raghunandan, T., Gonzalez, D. M., Dariolli, R., D'Souza, S. L., Yadaw, A. S., Hansen, J., et al. (2021) · Stem Cell Reports · doi:10.1016/j.stemcr.2021.10.005 · Cited by 26
Metadata
- Authors
- Mannhardt, I., Saleem, U., Mosqueira, D., Loos, M. F., Ulmer, B. M., Lemoine, M. D., Larsson, C., Améen, C., de Korte, T., Vlaming, M. L. H., Harris, K., Clements, P., Denning, C., Hansen, A., & Eschenhagen, T.
- Venue
- Stem Cell Reports
- Publisher
- Elsevier BV
- Published
- 2020-10
- Volume
- 15
- Issue
- 4
- Pages
- 983-998
- ISSN
- 2213-6711 (ISSN-L)
- OpenAlex
- W3093465023
- Cited by
- 73
- References
- 12
- FWCI
- 2.77
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Comparison of 10 Control hPSC Lines for Drug Screening in an Engineered Heart Tissue Format. https://app.cochat.ai/papers/10.1016/j.stemcr.2020.09.002
- The paper
- Mannhardt, I., Saleem, U., Mosqueira, D., Loos, M. F., Ulmer, B. M., Lemoine, M. D., Larsson, C., Améen, C., de Korte, T., Vlaming, M. L. H., Harris, K., Clements, P., Denning, C., Hansen, A., & Eschenhagen, T. (2020). Comparison of 10 Control hPSC Lines for Drug Screening in an Engineered Heart Tissue Format. Stem Cell Reports. https://doi.org/10.1016/j.stemcr.2020.09.002
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.